Darusentan in resistant hypertension: Lost in translation

Current Hypertension Reports

Volumn 12, Issue 1, 2010, Pages 1-3

  Enseleit, Frank ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DARUSENTAN; GUANFACINE; PLACEBO;

AGE DISTRIBUTION; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FLUID RETENTION; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; NOTE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION;

EID: 75549091926     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0081-y     Document Type: Note

References (13)

1. G Mancia G De Backer A Dominiczak, et al. 2007 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 12 1462 1536 17562668
2. Hypertension: uncontrolled and conquering the world [editorial]. Lancet 2007, 370(9587):539.
3. F Enseleit TF Luscher F Ruschitzka 2008 Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 17 8 1255 1263 10.1517/13543784.17.8.1255 1:CAS:528:DC%2BD1cXos1ChsL4%3D 18616421
4. J Schrader U Tebbe M Borries, et al. 1990 Plasma endothelin in normal probands and patients with nephrologic-rheumatologic and cardiovascular diseases Klin Wochenschr 68 15 774 779 10.1007/BF01647248 1:STN:280: DyaK3M%2FhtlKjug%3D%3D 2214602 (Pubitemid 20228521)
5. Y Saito K Nakao M Mukoyama H Imura 1990 Increased plasma endothelin level in patients with essential hypertension N Engl J Med 322 3 205 1:STN:280:DyaK3c%2FpvVSnsw%3D%3D 2403657
6. H Krum RJ Viskoper Y Lacourciere, et al. 1998 The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators N Engl J Med 338 12 784 790 10.1056/NEJM199803193381202 1:CAS:528:DyaK1cXitlChtbs%3D 9504938 (Pubitemid 28135984)
7. A receptor antagonist for treatment of hypertension Am J Hypertens 15 7 Pt 1 583 589 10.1016/S0895-7061(02)02933-3 1:CAS:528:DC%2BD38XlvVSktr4%3D 12118903 (Pubitemid 34734804)
8. HR Black GL Bakris MA Weber, et al. 2007 Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study J Clin Hypertens (Greenwich) 9 10 760 769 10.1111/j.1524-6175.2007.07244.x 1:CAS:528:DC%2BD2sXht12rt7%2FE
9. NS Kirkby PW Hadoke AJ Bagnall DJ Webb 2008 The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 153 6 1105 1119 10.1038/sj.bjp.0707516 1:CAS:528: DC%2BD1cXjtlelurc%3D 17965745
10. LE Spieker V Mitrovic G Noll, et al. 2000 Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators J Am Coll Cardiol 35 7 1745 1752 10.1016/S0735-1097(00)00649-5 1:CAS:528:DC%2BD3cXktlGlt7c%3D 10841220 (Pubitemid 30342852)
11. TF Luscher F Enseleit R Pacher, et al. 2002 Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT) Circulation 106 21 2666 2672 10.1161/01.CIR.0000038497.80095.E1 12438291 (Pubitemid 35364920)
12. A Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial Lancet 364 9431 347 354 10.1016/S0140-6736(04)16723-8 1:CAS:528:DC%2BD2cXmtVSktbg%3D 15276394 (Pubitemid 38970011)
13. Second pivotal phase III study of Gilead's darusentan for resistant hypertension misses primary endpoints [press release]. Foster City, CA: Gilead Sciences, Inc; December 14, 2009. Available at Accessed December 17, 2009 http://www.gilead.com/pr-1365747 . Accessed December 17, 2009.